Damien Goldberg is an Ophthalmology physician affiliated with Wolstan & Goldberg Eye Associates. OpenAlex indexes 40 publications with 1,338 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
23600 Telo Ave
Suite 100
Torrance, CA 905054035
Telephone
310-543-2611Registry record last updated 7 Oct 2014.
Clinical trials
- Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
Sponsor: Wolstan and Goldberg Eye Associates
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
Sponsor: Kala Pharmaceuticals, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year202518 payments
- Bausch & Lomb Americas Inc.Program year202512 payments
- Carl Zeiss Meditec USA, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
59.3%Prostaglandin Analog26.2%Latanoprost83%Lumigan9%Travoprost6%Bimatoprost2%Part D<11 patientsCarbonic Anhydrase Inhibitor11.4%Dorzolamide-Timolol58%Simbrinza17%Dorzolamide Hcl11%Acetazolamide Er7%Brinzolamide4%Cosopt Pf3%Part D<11 patients+ 7 more classes in this area
Cancer & immunology
19.7%Calcineurin inhibitor19.7%Restasis63%Cyclosporine35%Cequa2%Part D<11 patientsAnti-infectives
8.8%Fluoroquinolone Antibacterial6.4%Moxifloxacin100%Part D≥130 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor1%Valacyclovir100%Part D≥16 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Regional Differences in Changes in Travel under the Acuity Circles Policy
American Journal of Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”